Title :

Epidemiological impact and cost-effectiveness of introducing vaccination against serogroup B meningococcal disease in France.

Author(s) :

Lecocq, Héloïse [Auteur]
Parent Du Châtelet, Isabelle [Auteur]
Taha, Muhamed-Kheir [Auteur]
Levy-Bruhl, Daniel [Auteur]
DERVAUX, Benoit [Auteur]
METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694
Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]

Journal title :

Vaccine

Abbreviated title :

Vaccine

Volume number :

34

Pages :

2240-2250

Publisher :

Elsevier

Publication date :

2016-04

ISSN :

0264-410X

Keyword(s) :

Cost-effectiveness
Meningococcal
Serogroup B
Vaccine

HAL domain(s) :

Sciences du Vivant [q-bio]/Immunologie/Vaccinologie

English abstract : [en]

INTRODUCTION: Despite its low incidence in France, invasive serogroup B meningococcal disease remains a public health concern. A new vaccine against the disease, Bexsero(®), has been licensed in the EU. We studied the ...
Show more >INTRODUCTION: Despite its low incidence in France, invasive serogroup B meningococcal disease remains a public health concern. A new vaccine against the disease, Bexsero(®), has been licensed in the EU. We studied the epidemiological impact and cost-effectiveness of routine vaccination using Bexsero(®) in order to inform the decision-making process regarding its potential inclusion in the vaccination schedule. METHODS: A multi-generational Markov model was used. Time horizon was set to 100 years. Five vaccination strategies were evaluated: infants at 3, 5, 6 and 13 months, toddlers at 13, 15 and 27 months and adolescents at 15 years provided 2 doses one month apart. A booster dose at 15 years old and a catch-up for 15 years old subjects during the first 15 years of the programme were added to the infant and toddler strategies. Costs per QALY gained were computed from a restricted societal perspective including direct costs only. Herd immunity was simulated in an alternative base-case scenario and sensitivity analyses. RESULTS: In the base-case analysis without herd immunity and with all cohorts vaccinated, at \u20AC 40 per vaccine dose, routine infant vaccination would provide the lowest cost per QALY gained (\u20AC 380,973) despite only preventing 18% of cases. Under the assumption of herd immunity, the adolescent vaccination would provide the lowest cost per QALY gained (\u20AC 135,902) preventing 24% of cases. Infant vaccination with a late booster and catch-up would prevent 51% of cases with a cost of \u20AC 188,511 per QALY gained. CONCLUSIONS: Given current meningococcal epidemiology in France and the available data on the protection provided by Bexsero(®), our modelling work showed that routine vaccination against serogroup B meningococcal disease is not cost-effective.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

CHU Lille
Université de Lille

Collections :

• METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694

Submission date :

2020-06-08T14:11:35Z